October 12, 2012
Dave Hinds is a Principal Scientist in Statistical Genetics. 23andMe is passionate about research on a group of rare blood disorders called myeloproliferative neoplasms, or MPNs. Physicians who study these disorders consider them to be blood cancers, though individual prognoses can vary widely — some [...]
October 1, 2012
Ashley Gould, 23andMe's Vice President Corporate Development and Chief Legal Officer We recently topped our goal of enrolling 1,000 people with a group of rare blood disorders known as myeloproliferative neoplasms, or MPNs. As a testament to the passion of the people who’ve enrolled in our MPN Research [...]
